Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Mechanisms of Heart Failure and Implications for Clinical Translation Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Premium Access ESC Congress 2020

ESC 365 is supported by

ESC 365 is supported by